BPC
KPTI icon

Banque Pictet & Cie’s Karyopharm Therapeutics KPTI Stock Holding History

Banque Pictet & Cie’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-345
Closed -$241K – 475
2014
Q2 		$241K Buy
+345
New +$161K 0.01% 402

Other funds holding KPTI

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
FCMI
Foresite Capital Management I Larkspur, California $21.4M AUM 80.48% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Banque Pictet & Cie's KPTI Position: Q3 2014 in Review

Banque Pictet & Cie sold out of Karyopharm Therapeutics (KPTI) in Q3 2014, closing a stake of 345 shares — an estimated $241K sold.

Banque Pictet & Cie first reported a position in KPTI in Q2 2014 and held it in 1 quarter. The position peaked at $241K in Q2 2014. 71 funds tracked by Wall St. Rank hold KPTI as of Q3 2014.

  • Banque Pictet & Cie reported no remaining Karyopharm Therapeutics position as of Q3 2014 after selling out during the quarter.
  • Banque Pictet & Cie sold 345 Karyopharm Therapeutics shares in Q3 2014, an estimated $241K.
  • Banque Pictet & Cie first reported a position in Karyopharm Therapeutics in Q2 2014 and held it in 1 quarter.
  • Banque Pictet & Cie's Karyopharm Therapeutics position peaked at $241K in Q2 2014.
  • 71 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q3 2014.

Based on Banque Pictet & Cie's 13F filing for Q3 2014, filed 7 Nov 2014.